Cipla Limited (NSE:CIPLA)
India · Delayed Price · Currency is INR | Market Cap | 1.09T -7.8% |
| Revenue (ttm) | 278.28B +2.1% |
| Net Income | 38.79B -26.4% |
| EPS | 48.00 -26.4% |
| Shares Out | 807.80M |
| PE Ratio | 28.16 |
| Forward PE | 26.38 |
| Dividend | 13.00 (0.96%) |
| Ex-Dividend Date | Jun 5, 2026 |
| Volume | 1,476,641 |
| Open | 1,355.00 |
| Previous Close | 1,355.50 |
| Day's Range | 1,346.60 - 1,362.30 |
| 52-Week Range | 1,165.70 - 1,673.00 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 1,456.73 (+7.76%) |
| Earnings Date | Jul 23, 2026 |
About Cipla
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, ... [Read more]
Financial Performance
In fiscal year 2026, Cipla's revenue was 278.28 billion, an increase of 2.06% compared to the previous year's 272.67 billion. Earnings were 38.79 billion, a decrease of -26.43%.
Financial StatementsAnalyst Summary
According to 37 analysts, the average rating for CIPLA stock is "Buy." The 12-month stock price target is ₹1,457, which is an increase of 7.76% from the latest price.
News
Cipla advertises Reactin Plus, FDA says recall stock in state
Maharashtra FDA issued notice to Cipla Pharma & Life Sciences to recall Schedule H drug Reactin Plus statewide over prohibited advertising; ₹11.19 lakh seized.
Pharma sector stocks today, June 17: Aurobindo Pharma gains 2.26%, Panacea Biotech falls 1.80%, Cipla down 0.32%
Pharma stocks traded mixed on June 17, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Cipla appoints Shivam Puri as CEO of One India Business effective 1st July 2026
Cipla has announced the appointment of Mr Shivam Puri as the Chief Executive Officer of its One India Business, effective from 1st July 2026. Mr Puri, who is currently the…
Cipla's Goa facility receives VAI classification from USFDA
Cipla has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection at the company's manufacturing facility in Verna, Goa, as Voluntary Action Indicate...
Cipla corrects e-voting end date for 90th AGM to 24th June 2026
Cipla has issued a corrigendum to its previous announcement regarding the 90th Annual General Meeting (AGM) and the Integrated Annual Report for the financial year 2025-26. The company clarified that…
Pharma stocks in focus: Nomura highlights strong Zydus growth, Lupin and Cipla see sales decline in April
Pharma stocks are likely to remain in focus after Nomura's analysis of April 2026 IQVIA data highlighted divergent trends among major Indian pharmaceutical companies in the US generics market. Accordi...
Cipla announces tax deduction details for final dividend of ₹13 per share
Cipla has informed its shareholders about the tax deduction at source on the final dividend for the financial year 2025-26. The company has recommended a final dividend of ₹13 per…
Cipla reports 40.82% export contribution to turnover for FY 2025-26
Cipla Limited has released its Business Responsibility and Sustainability Report for the financial year 2025-26, highlighting key operational and financial metrics. A significant point from the report...
Bharti Airtel, Cipla & more: Top stocks to watch on May 18
Jefferies raised Bharti Airtel's target price to Rs 2,350 on strong Q4FY26 performance, while JP Morgan upgraded Cipla to overweight citing improved earnings visibility and attractive valuations. Morg...
Pharma sector stocks today, May 14: Cipla jumps 7.15%, Zydus Lifesciences rises 4.01%, Strides Pharma up 2.20%
Pharmaceutical stocks opened strongly on May 14 2026 during the early morning trading session. The sector witnessed broad-based buying interest with most stocks trading in the green. The BSE Healthcar...
Cipla Transcript: Q4 25/26
Q4 and FY26 saw robust growth across all geographies, with India and North America leading performance and key regulatory approvals boosting the pipeline. FY27 guidance targets double-digit India growth, a $1B U.S. run rate, and 18.5%-20% EBITDA margin, with risks from geopolitical factors.
Cipla Quarterly report: Q4 2026
Cipla has published its Q4 2026 quarterly earnings report on May 13, 2026.
Cipla Slides: Q4 2026
Cipla has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Cipla Annual report: Q4 2026
Cipla has published its Q4 2026 annual report on May 13, 2026.
CIPLA Reports 54.6% Drop in Q4 Net Profit Amid Rising Costs
CIPLA Reports 54.6% Drop in Q4 Net Profit Amid Rising Costs
Cipla appoints Sushrut Kulkarni as Global Chief for Integrated Product Development
Cipla has announced the appointment of Mr Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), effective from 18th May 2026. This strategic appointment was approved dur...
Cipla reports Rs 28,163 crore revenue for FY26 with robust growth in India and Africa
Cipla Limited announced its audited consolidated financial results for the quarter ended 31st March 2026, reporting a significant annual revenue of ₹28,163 crore for FY26. The company achieved double-...
Cipla declares ₹13 dividend despite Q4 profit crash — what went wrong and should investors worry?
Cipla Limited's Q4 FY26 results landed with a thud on May 13 — net profit down 55%, EBITDA margin more than halved, and a miss against analyst estimates so sharp…
Cipla Q4 Results: Profit falls 55% on a YoY basis, margin contracts sharply
Cipla Ltd. reported a decline in consolidated profitability for the quarter ended March 31, 2026, as operating margins weakened amid higher expenses. Revenue from operations during Q4 FY26 stood at…
Cohance Lifesciences Hits 20% Upper Circuit After Appointing Former Cipla CEO Umang Vohra as Chairman and Group CEO
Shares of Cohance Lifesciences hit the 20% upper circuit, surging ₹72 to ₹432.10 on the NSE as of 9:38 AM IST on Monday, April 27, after the company announced the…
Cipla faces $100 million revenue risk as USFDA alert delays restart beyond FY27, says Macquarie
Cipla may face a significant setback to its US growth trajectory after a regulatory action impacted supplies of a key product, with brokerage firm Macquarie flagging a potential revenue risk…
Cipla Shares Fall 3% as Partner Unit Gets FDA Import Alert, Lanreotide Revenue at Risk
Cipla shares dropped 2.93% or ₹38.20 to ₹1,267.70 on the NSE as of 9:25 AM IST on April 24, touching an intraday low of ₹1,254.10 in early trade, after it…
Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup
A busy morning for broker calls with Infosys drawing the most divided analyst opinion after its Q4 FY26 results, Dr Reddy's receiving back-to-back downgrades on the Semaglutide opportunity, Cipla gett...
Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more
Indian equity benchmarks ended lower on Thursday, April 23, 2026, with the NIFTY 50 closing at 24,173.05, down 205.05 points (-0.84%). Despite the broader market weakness, select stocks managed to…
Cipla gets USFDA nod for first AB-rated generic of Ventolin HFA
Cipla Limited on April 23 announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Albuterol…